FFR-guided PCI, ISCHEMIA trial challenged, QFR, and one of the most important studies of 2021 are discussed by John Mandrola, MD, in this week’s podcast. To read a partial transcript or to comment, visit: [ Ссылка ]
I - FFR-Guided PCI
- FFR-Guided PCI Falls Short vs CABG in Multivessel CAD: FAME 3 [ Ссылка ]
- Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery [ Ссылка ]
- The fallacies of fractional flow reserve [ Ссылка ]
II - ISCHEMIA-Trial Challenged
- How Applicable is ISCHEMIA Trial to US Clinical Practice? [ Ссылка ]
- Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population [ Ссылка ]
- The Glass Is at Least Half Full [ Ссылка ]
- Initial Invasive or Conservative Strategy for Stable Coronary Disease [ Ссылка ]
III - QFR
- FAVOR III China: QFR-Guided PCI Shows Advantage Over Angiography [ Ссылка ]
- Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial [ Ссылка ]02248-0
Features:
- The MI–Mortality Mismatch: When Lowering MI Doesn't Extend Life [ Ссылка ]
- Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease [ Ссылка ]
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine [ Ссылка ]
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. [ Ссылка ]
Questions or feedback, please contact news@medscape.net
